Serum/Plasma MicroRNA Markers for Detecting Gastric Cancer and Its Application

Abstract

The invention discloses a gastric cancer detection serum / plasma miRNA (micro ribonucleic acid) marker and an application thereof. The biomarker is any one or more out of miR-148a, miR-142, miR-26a and miR-195, wherein miR-148a is as shown in SEQIDNO:1; miR-142 is as shown in SEQIDNO:2; miR-26a is as shown in SEQIDNO:3; miR-195 is as shown in SEQIDNO:4. According to the marker and the application thereof, a gastric cancer patient tissue miRNA chip expression profile is combined with a serum / plasma miRNA chip expression profile for use for the first time, and the screened miRNA marker is tumor-specific, high in sensitivity and applicable to large-scale screening, and gastric cancer can be simply diagnosed.

Description

Technical field [0001] This patent belongs to the fields of biotechnology and oncology, relates to the application of serum / plasma microRNA (microRNA, miRNA for short), and discloses a serum / plasma miRNA for detecting gastric cancer and its application. Background technique [0002] Gastric cancer is one of the most common tumors in the world. Although the overall incidence of gastric cancer has shown a downward trend in recent years, the absolute number of cases of gastric cancer is still very large. Morbidity and mortality occupy the fourth and the first place in malignant tumors. Two people. In my country, the incidence and mortality of gastric cancer ranks first among all types of tumors. The number of newly diagnosed patients every year reaches more than 300,000, of which two-thirds are advanced gastric cancer, and the age of onset has a clear trend of younger. Early gastric cancer is mostly asymptomatic or only mild. When the clinical symptoms are obvious, the condition i...

AI Technical Summary

Problems solved by technology

[0003] The diagnosis of gastric cancer is generally based on clinical symptoms, combined with signs and endoscopic examination, X-ray barium meal examination, B-mode ultrasonography, CT examination, magnetic resonance imaging MRI examination and exfoliative cytology examination, but these methods are not effective in early diagnosis. There are certain defects: Imaging examinations have certain limitations in the diagnosis of early gastric cancer, improper endoscopic examination and exfoliated cell examination, or insufficient human experience will lead to misdiagnosis or missed diagnosis

Whether the expression of these miRNAs in serum / plasma is consistent with that in gastric cancer tissue, and whether it can be used as a specific marker for gastric cancer for the diagnosis of gastric cancer remains to be further studied

Images